Abstract 139P
Background
No specialized prognosis model for gastric cancer patients with peritoneal metastasis (GCPM) exists for intraoperative clinical decision-making. This study aims to establish a new prognostic model to provide individual treatment decisions for GCPM.
Methods
This retrospective analysis included 324 GCPM diagnosed pathologically by laparoscopy from January 2007 to January 2018 who were randomly assigned to different sets (227 in the training set and 97 in the validation set). A nomogram was established from preoperative and intraoperative variables determined by the Cox model. The peritoneal metastasis nomogram (PMN), was compared with the 15th peritoneal metastasis staging system (P1abc) for its predictive ability and clinical applicability.
Results
The median survival time was 8 (range, 1-90) months. In the training set, each PMN substage had significantly different survival curves (P<0.001), and the PMN was superior to P1abc based on the results of time-dependent receiver operating characteristic curve, C-index, Akaike information criterion and likelihood ratio chi-square analyses. In the validation set, the PMN was also better than P1abc in terms of its predictive ability. Of the PMN1 patients, those undergoing palliative resection (PR) had better OS than those undergoing exploratory surgery (ES) (P<0.05). Among the patients undergoing ES, those who received chemotherapy exhibited better OS than those who did not (P<0.05). Among the patients with PR, only PMN1 patients exhibited better OS following chemotherapy (P<0.05).
Conclusions
We developed and validated a simple, specific peritoneal metastasis model for GCPM that can predict prognosis well and guide treatment decisions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Scientific and Technological Innovation Joint Capital Projects of Fujian Province.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
123P - The clinical value of prognostic nutritional index in esophagogastric junctional adenocarcinoma patients with anastomotic leakage after surgery
Presenter: Yan Wang
Session: e-Poster Display Session
124P - Prospective evaluation of pattern of care and quality of life in patients undergoing esophagectomy at a high-volume regional cancer centre in South India
Presenter: Faheem Abdulla
Session: e-Poster Display Session
125P - Analysis of esophageal cancer incidence for last 20 years in Uzbekistan
Presenter: Abrorjon Yusupbekov
Session: e-Poster Display Session
126P - A phase II study of rh-endostatin combined with irinotecan plus cisplatin as the second-line treatment for advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jianhua Chang
Session: e-Poster Display Session
128P - Clinical update with plasma and tumour-based genomic analyses in expansion part of phase I study of selective FGFR inhibitor E7090
Presenter: Chigusa Morizane
Session: e-Poster Display Session
129P - Exploration of the best candidates for splenic hilar lymph node dissection (No.10 LND) based on long-term survival: Stage IIIA proximal gastric cancer may benefit from No.10 LND
Presenter: Zu-Kai Wang
Session: e-Poster Display Session
130P - Reappraisal of the role of no. 10 lymphadenectomy for proximal gastric cancer in the era of minimal invasive surgery during total gastrectomy: A pooled analysis of 4 prospective trials
Presenter: Qing Zhong
Session: e-Poster Display Session
131P - Prognostic value of tumour regression grading (TRG) in patients treated with neoadjuvant chemotherapy plus surgery for gastric cancer
Presenter: Jian-Wei Xie
Session: e-Poster Display Session
132P - Impact of increasing age on cancer- and noncancer-specific mortality in patients with gastric cancer treated by radical surgery: A competing risk analysis
Presenter: Long-Long Cao
Session: e-Poster Display Session